Drug Search Results
More Filters [+]

Sivelestat

Alternative Names: sivelestat
Latest Update: 2024-11-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ELA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: China | Korea

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sivelestat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn

Phase 3: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Sepsis

Phase 2: Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2400086632

N/A

Not yet recruiting

Unknown

2027-04-24

ChiCTR2200059102

N/A

Not yet recruiting

Acute Lung Injury

2027-03-01

ChiCTR2400086486

N/A

Not yet recruiting

Acute Respiratory Distress Syndrome

2026-12-31

2023-LCYJ-MS-26

P3

Not yet recruiting

Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Acute Respiratory Distress Syndrome

2026-06-30

Recent News Events